US Stock MarketDetailed Quotes
ACRS Aclaris Therapeutics
- 3.800
- -0.520-12.04%
Close Nov 22 16:00 ET
- 4.010
- +0.210+5.53%
Post 20:01 ET
271.44MMarket Cap-7307P/E (TTM)
4.440High3.800Low2.99MVolume4.280Open4.320Pre Close12.03MTurnover5.47%Turnover RatioLossP/E (Static)71.43MShares5.17052wk High2.09P/B207.54MFloat Cap0.77052wk Low--Dividend TTM54.61MShs Float33.880Historical High--Div YieldTTM14.82%Amplitude0.590Historical Low4.026Avg Price1Lot Size
Aclaris Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -53.18%4.35M | 47.99%2.77M | -5.14%2.4M | 5.03%31.25M | 126.62%17.57M | -51.19%9.28M | 22.32%1.87M | 73.98%2.53M | 340.05%29.75M | 416.52%7.75M |
| Operating revenue | -53.18%4.35M | 47.99%2.77M | -5.14%2.4M | 5.95%31.25M | 131.55%17.57M | -51.12%9.28M | 24.77%1.87M | 77.65%2.53M | 344.27%29.5M | 415.84%7.59M |
| Cost of revenue | -70.61%2.41M | 19.91%1.91M | -1.55%1.84M | 51.18%18.08M | 324.57%6.43M | -0.38%8.19M | 49.06%1.59M | 61.82%1.87M | 153.77%11.96M | 31.77%1.51M |
| Gross profit | 77.80%1.94M | 209.39%857K | -15.33%558K | -25.99%13.17M | 78.59%11.14M | -89.90%1.09M | -39.78%277K | 121.14%659K | 768.75%17.79M | 1,672.44%6.24M |
| Operating expense | -62.15%11.61M | -58.52%13.51M | -46.81%16.69M | 25.78%129.48M | 23.54%34.86M | 4.09%30.67M | 31.05%32.57M | 53.77%31.38M | 52.67%102.95M | 34.08%28.22M |
| Selling and administrative expenses | -16.84%5.65M | -34.87%4.75M | -22.14%6.84M | 23.73%31.1M | 14.95%8.21M | 16.94%6.8M | 20.10%7.3M | 44.12%8.79M | 6.41%25.13M | 2.92%7.15M |
| -General and administrative expense | -16.84%5.65M | -34.87%4.75M | -22.14%6.84M | 23.73%31.1M | 14.95%8.21M | 16.94%6.8M | 20.10%7.3M | 44.12%8.79M | 6.41%25.13M | 2.92%7.15M |
| Research and development costs | -75.05%5.96M | -65.35%8.76M | -56.41%9.85M | 26.44%98.38M | 26.45%26.65M | 0.93%23.88M | 34.59%25.28M | 57.88%22.59M | 77.60%77.81M | 49.43%21.07M |
| Operating profit | 67.31%-9.67M | 60.82%-12.65M | 47.49%-16.13M | -36.59%-116.31M | -7.91%-23.72M | -58.42%-29.58M | -32.39%-32.29M | -52.77%-30.72M | -30.24%-85.15M | -6.21%-21.98M |
| Net non-operating interest income expense | -14.03%1.99M | 2.32M | ||||||||
| Non-operating interest income | -14.03%1.99M | ---- | ---- | ---- | ---- | --2.32M | ---- | ---- | ---- | ---- |
| Other net income (expense) | 104.72%94K | -38.79%1.67M | -131.67%-810K | 1,665.91%27.47M | 598.23%28.18M | -55.95%-1.99M | -29.44%2.73M | 94.08%2.56M | 93.12%-1.75M | -167.93%-5.66M |
| Special income (charges) | 59.86%-800K | -141.75%-200K | -450.00%-2.8M | 503.34%18.96M | 377.06%19.67M | 9.41%-1.99M | -85.91%479K | -33.33%800K | 80.69%-4.7M | -222.73%-7.1M |
| -Less：Restructuring and merger&acquisition | -52.94%800K | 113.33%200K | 450.00%2.8M | -672.34%-26.9M | -470.42%-26.3M | -22.73%1.7M | 55.88%-1.5M | 33.33%-800K | -80.69%4.7M | 222.73%7.1M |
| -Less:Impairment of capital assets | ---- | ---- | ---- | --6.63M | ---- | ---- | ---- | ---- | --0 | ---- |
| -Write off | --0 | --0 | ---- | --1.31M | --0 | --293K | --1.02M | ---- | --0 | --0 |
| Other non- operating income (expenses) | --894K | -16.83%1.87M | 13.20%1.99M | 188.83%8.51M | ---- | ---- | 386.15%2.25M | 1,389.83%1.76M | 357.97%2.95M | 1,522.47%1.44M |
| Income before tax | 74.07%-7.59M | 62.85%-10.99M | 39.84%-16.94M | -2.23%-88.85M | 93.28%-1.86M | -46.66%-29.26M | -44.01%-29.57M | -49.87%-28.16M | 4.35%-86.91M | -21.18%-27.64M |
| Income tax | -367K | 0 | ||||||||
| Net income | 74.07%-7.59M | 62.85%-10.99M | 39.84%-16.94M | -1.81%-88.48M | 94.60%-1.49M | -46.66%-29.26M | -44.01%-29.57M | -49.87%-28.16M | 4.35%-86.91M | -21.18%-27.64M |
| Net income continuous Operations | 74.07%-7.59M | 62.85%-10.99M | 39.84%-16.94M | -1.81%-88.48M | 94.60%-1.49M | -46.66%-29.26M | -44.01%-29.57M | -49.87%-28.16M | 4.35%-86.91M | -21.18%-27.64M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 74.07%-7.59M | 62.85%-10.99M | 39.84%-16.94M | -1.81%-88.48M | 94.60%-1.49M | -46.66%-29.26M | -44.01%-29.57M | -49.87%-28.16M | 4.35%-86.91M | -21.18%-27.64M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 74.07%-7.59M | 62.85%-10.99M | 39.84%-16.94M | -1.81%-88.48M | 94.60%-1.49M | -46.66%-29.26M | -44.01%-29.57M | -49.87%-28.16M | 4.35%-86.91M | -21.18%-27.64M |
| Basic earnings per share | 73.17%-0.11 | 64.29%-0.15 | 42.86%-0.24 | 4.51%-1.27 | 95.12%-0.02 | -36.67%-0.41 | -35.48%-0.42 | -35.48%-0.42 | 16.88%-1.33 | -10.81%-0.41 |
| Diluted earnings per share | 73.17%-0.11 | 64.29%-0.15 | 42.86%-0.24 | 4.51%-1.27 | 95.12%-0.02 | -36.67%-0.41 | -35.48%-0.42 | -35.48%-0.42 | 16.88%-1.33 | -10.81%-0.41 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data